<p>GOLDEN THROAT (06896.HK) announced its performance for the fiscal year 2025, with revenue of RMB 943 million, a year-on-year decrease of 20.4%; gross profit of RMB 717 million, down 19.8%. It recorded a net profit of RMB 251 million, a decline of 21.2%, with earnings per share of 33.98 cents. The final dividend is set at HKD 0.34, compared to HKD 0.50 in the same period last year</p>

512010

520880

513700

<p>GOLDEN THROAT announced its 2025 annual performance, with revenue of 943 million RMB, a year-on-year decrease of 20.4%; gross profit of 717 million RMB, down 19.8%. It recorded a net profit of 251 million RMB, a decline of 21.2%, with earnings per share of 33.98 cents. The final dividend is 34 Hong Kong cents, compared to 50 Hong Kong cents in the same period last year</p>

AASTOCKS

E Fund CSI 300 Health Care ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

Yinhua CSI Innovative Drugs Industry ETF

China Universal 800 Health Care ETF

GOLDEN THROAT

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai SSE STAR Brand Name Drug ETF

Guotai CSI Bio-medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

In the report, GOLDEN THROAT's annual net profit is 251 million RMB, a decrease of 21.2%, with a final dividend of 34 Hong Kong cents